Paying users zone. Data is covered by 
.
Get to Celgene Corp. for $13.99, or
get to whole website for at least 3 months from $49.99.
Return on Assets (ROA)
since 2005
Difficulty: Beginner
Calculation
Celgene Corp., ROA, long-term trends, calculation
| ROA | = | 100 | × | Net income (loss) attributable to Celgene1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2005 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2006 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2007 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2008 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2009 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2010 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2011 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2012 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2013 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2014 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2015 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2016 | % |
= | 100 | × | |
÷ | |
| Dec 31, 2017 | % |
= | 100 | × | |
÷ | |
1 USD $ in millions
Source: Based on data from Celgene Corp. Annual Reports
Comparison to Competitors
Celgene Corp., ROA, long-term trends, comparison to competitors
| Celgene Corp. | Abbott Laboratories | AbbVie Inc. | Allergan PLC | Amgen Inc. | Biogen Inc. | Bristol-Myers Squibb Co. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2005 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2006 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2007 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2008 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2009 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2010 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2011 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2012 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2013 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2014 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2015 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2016 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
| Dec 31, 2017 | % |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
% |
Source: Based on data from Celgene Corp. Annual Reports
Comparison to Pharmaceuticals & Biotechnology Sector
Celgene Corp., ROA, long-term trends, comparison to Pharmaceuticals & Biotechnology sector
| Celgene Corp. | Pharmaceuticals & Biotechnology | |
|---|---|---|
| Dec 31, 2005 | % |
% |
| Dec 31, 2006 | % |
% |
| Dec 31, 2007 | % |
% |
| Dec 31, 2008 | % |
% |
| Dec 31, 2009 | % |
% |
| Dec 31, 2010 | % |
% |
| Dec 31, 2011 | % |
% |
| Dec 31, 2012 | % |
% |
| Dec 31, 2013 | % |
% |
| Dec 31, 2014 | % |
% |
| Dec 31, 2015 | % |
% |
| Dec 31, 2016 | % |
% |
| Dec 31, 2017 | % |
% |
Source: Based on data from Celgene Corp. Annual Reports
Comparison to Health Care Industry
Celgene Corp., ROA, long-term trends, comparison to Health Care industry
| Celgene Corp. | Health Care | |
|---|---|---|
| Dec 31, 2005 | % |
% |
| Dec 31, 2006 | % |
% |
| Dec 31, 2007 | % |
% |
| Dec 31, 2008 | % |
% |
| Dec 31, 2009 | % |
% |
| Dec 31, 2010 | % |
% |
| Dec 31, 2011 | % |
% |
| Dec 31, 2012 | % |
% |
| Dec 31, 2013 | % |
% |
| Dec 31, 2014 | % |
% |
| Dec 31, 2015 | % |
% |
| Dec 31, 2016 | % |
% |
| Dec 31, 2017 | % |
% |
Source: Based on data from Celgene Corp. Annual Reports
